Phase 1 trial of BA 2101
Latest Information Update: 23 Feb 2024
At a glance
- Drugs BA 2101 (Primary)
- Indications Asthma; Atopic dermatitis; Prurigo nodularis; Pruritus; Rhinosinusitis; Sinusitis; Urticaria
- Focus Adverse reactions
Most Recent Events
- 26 Jan 2024 Status changed from recruiting to completed, according to a Shandong Boan Biotechnology media release.
- 21 Feb 2023 New trial record